Bone turnover markers in postmenopausal breast cancer treated with fulvestrant - A pilot study

Breast

Volumn 18, Issue 3, 2009, Pages 204-207

  Agrawal, A ^a   Hannon, R A ^b   Cheung, K L ^a   Eastell, R ^b   Robertson, J F R ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Antiestrogen; Bone markers; Breast cancer; Fulvestrant; Locally advanced

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL PROPEPTIDE OF PROCOLLAGEN TYPE 1; CARBOXY TERMINAL TELOPEPTIDE; FULVESTRANT; PROCOLLAGEN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DISEASE; BONE MASS; BONE METABOLISM; BONE TURNOVER; BREAST CANCER; CANCER HORMONE THERAPY; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; PILOT STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 67349267301     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2009.04.002     Document Type: Article

References (23)

1. Eastell R., Hannon R.A., Cuzick J., Dowsett M., Clack G., and Adams J.E. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination (ATAC) trial (18233230). J Bone Miner Res 21 (2006) 1215-1223
2. Love R.R., Mazess R.B., Barden H.S., Epstein S., Newcomb P.A., Jordan V.C., et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326 (1992) 852-856
3. Chang J., Powles T.J., Ashley S.E., Gregory R.K., Tidy V.A., Treleaven J.G., et al. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann Oncol 7 (1996) 671-675
4. Love R.R., Mazess R.B., Tormey D.C., Barden H.S., Newcomb P.A., and Jordan V.C. Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat 12 (1988) 297-302
5. Addo S., Yates R.A., and Laight A. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br J Cancer 87 (2002) 1354-1359
6. Wakeling A.E. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer 7 (2000) 17-28
7. Wakeling A.E. The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Res Treat 25 (1993) 1-9
8. Robertson J., Osborne C., Howell A., Jones S.E., Mauriac L., Ellis M., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women. Cancer 98 (2003) 229-238
9. Howell A., Pippen J., Elledge R., Mauriac L., Vergote I., Jones S., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma. Cancer 104 (2005) 236-239
10. Howell A., Robertson J.F.R., Abram P., Lichinitser M.R., Elledge R., Bajetta E., et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22 (2004) 1605-1613
11. Anon. Lancet (1974) 38-39
12. Hayward J., Carbone P., and Heuson J. Assessment of response to therapy in advanced breast cancer. Cancer 39 (1977) 1289-1293
13. Looker A., Bauer D., Chesnut III C., Gundberg C., Hochberg M., Klee G., et al. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int 11 (2000) 467-480
14. Bjarnason N.H., Henriksen E.E., Alexandersen P., Christgau S., Henriksen D.B., and Christiansen C. Mechanism of circadian variation in bone resorption. Bone 30 (2002) 307-313
15. Vasikaran S.D. Utility of biochemical markers of bone turnover and bone mineral density in management of osteoporosis. Crit Rev Clin Lab Sci 45 (2008) 221-258
16. Eastell R., and Hannon R. Biomarkers of bone health and osteoporosis risk. Proc Nutr Soc 67 (2008) 157-162
17. Gallagher A., Chambers T.J., and Tobias J.H. The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats. Endocrinology 133 (1993) 2787-2791
18. Sibonga J.D., Dobnig H., Harden R.M., and Turner R.T. Effect of the high-affinity estrogen receptor ligand ICI 182,780 on the rat tibia. Endocrinology 139 (1998) 3736-3742
19. Lea C.K., and Flanagan A.M. Ovarian androgens protect against bone loss in rats made oestrogen deficient by treatment with ICI 182,780. J Endocrinol 160 (1999) 111-117
20. Donnez J., Hervais Vivancos B., Kudela M., Audebert A., and Jadoul P. A randomized, placebo-controlled, dose-ranging trial comparing fulvestrant with goserelin in premenopausal patients with uterine fibroids awaiting hysterectomy. Fertil Steril 79 (2003) 1380
21. Kuter I., Hegg R., Singer C., Badwe R., and Lowe E. Fulvestrant 500 mg vs 250 mg: first results from NEWEST, a randomized, phase II neoadjuvant trial in postmenopausal women with locally advanced, estrogen receptor-positive breast cancer. Breast Cancer Res Treat 106 (2007) S7
22. Journe F., Chaboteaux C., Magne N., Duvillier H., Laurent G., and Body J.J. Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines. Breast Cancer Res 8 (2006) R2
23. Hillner B.E., Ingle J.N., Chlebowski R.T., Gralow J., Yee G.C., Janjan N.A., et al. American Society of Clinical Oncology 2003 Update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 (2003) 4042-4057